HKHan-Seop Kim

Han-Seop Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Han-Seop Kim has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Binna Seol

    Stem Cell Research Laboratory, Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

    1 shared publication
  • Cho Lok Song

    Stem Cell Research Laboratory, Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

    1 shared publication
  • Jae Yun Kim

    Stem Cell Research Laboratory, Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

    1 shared publication
  • Ji Eun Jeong

    Stem Cell Research Laboratory, Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea

    1 shared publication
  • Yee Sook Cho

    Stem Cell Research Laboratory, Immunotherapy Research Center Korea Research Institute of Bioscience and Biotechnology (KRIBB) Daejeon South Korea

    1 shared publication

Latest Publications

  • Directly reprogrammed natural killer cells for cancer immunotherapy

    by Han-Seop Kim, Jae Yun Kim, Binna Seol, Cho Lok Song, Ji Eun Jeong, Yee Sook Cho

    Efficacious and accessible sources of natural killer (NK) cells would widen their use as immunotherapeutics, particularly for solid cancers. Here, we show that human somatic cells can be directly reprogrammed into NK cells with a CD56brightCD16bright phenotype using pluripotency transcription factors and an optimized reprogramming medium. The directly reprogrammed NK cells have strong innate–adaptive immunomodulatory activity and are highly potent against a wide range of cancer cells, including difficult-to-treat solid cancers and cancer stem cells. Both directly reprogrammed NK cells bearing a cancer-specific chimeric antigen receptor and reprogrammed NK cells in combination with antibodies competent for antibody-dependent cell-mediated cytotoxicity led to selective anticancer effects with augmented potency. The direct reprogramming of human somatic cells into NK cells is amenable to the production of autologous and allogeneic NK cells, and will facilitate the design and testing of cancer immunotherapies and combination therapies.